Evotec Shares Jump After Triton Acquires Stake

Dow Jones11-11

By Maitane Sardon

Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock.

Luxembourg-based private equity firm Triton acquired a total of 17,730,913 ordinary shares in a series of transactions totaling 131 million euros ($140.4 million), the German biotechnology company said.

Shares traded 12% higher at 8.52 euros in European early morning trading on Monday.

Triton, which also owns pharmaceutical services companies Bormioli Pharma and Clinigen, now holds 9.99% of Evotec's stock.

Evotec's market performance remains one of the worst in the sector so far this year, with shares down more than 60% over the last 12 months.

"In a risk-off environment, Evotec's mixed model that includes sharing risk with partners, plus its internal product R&D, aren't appreciated by investors," RBC Capital Markets analysts said in a research note. Shares have suffered due to self-inflicted issues that have contributed to low margins and stock rating downgrades, they added, noting that the stock can outperform in the long term, potentially catalyzed by Triton's stock acquisition.

Write to Maitane Sardon at maitane.sardon@wsj.com

(END) Dow Jones Newswires

November 11, 2024 05:22 ET (10:22 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482206659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482206659","market":"hk","top_or_hot":-1,"title":"Evotec Shares Jump After Triton Acquires Stake","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Maitane Sardon \n</p>\n<pre>\n \n</pre>\n<p>\n  Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock. \n</p>\n<p>\n  Luxembourg-based private equity firm Triton acquired a total of  17,730,913 ordinary shares in a series of transactions totaling 131 million euros ($140.4 million), the German biotechnology company said. \n</p>\n<p>\n  Shares traded 12% higher at 8.52 euros in European early morning trading on Monday. \n</p>\n<p>\n  Triton, which also owns pharmaceutical services companies Bormioli Pharma and Clinigen, now holds 9.99% of Evotec's stock. \n</p>\n<p>\n  Evotec's market performance remains one of the worst in the sector so far this year, with shares down more than 60% over the last 12 months. \n</p>\n<p>\n  \"In a risk-off environment, Evotec's mixed model that includes sharing risk with partners, plus its internal product R&amp;D, aren't appreciated by investors,\" RBC Capital Markets analysts said in a research note. Shares have suffered due to self-inflicted issues that have contributed to low margins and stock rating downgrades, they added, noting that the stock can outperform in the long term, potentially catalyzed by Triton's stock acquisition. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Maitane Sardon at maitane.sardon@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2024 05:22 ET (10:22 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evotec Shares Jump After Triton Acquires Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvotec Shares Jump After Triton Acquires Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 18:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Maitane Sardon \n\n\n \n\n\n  Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock. \n\n\n  Luxembourg-based private equity firm Triton acquired a ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRTN","symbol_name":"Triton International Limited","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2482206659","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482206659","pubTimestamp":1731320520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock.Luxembourg-based private equity firm Triton acquired a total of  17,730,913 ordinary shares in a series of transactions totaling 131 million euros , the German biotechnology company said.Shares traded 12% higher at 8.52 euros in European early morning trading on Monday.Triton, which also owns pharmaceutical services companies Bormioli Pharma and Clinigen, now holds 9.99% of Evotec's stock.Evotec's market performance remains one of the worst in the sector so far this year, with shares down more than 60% over the last 12 months.\"In a risk-off environment, Evotec's mixed model that includes sharing risk with partners, plus its internal product R&D, aren't appreciated by investors,\" RBC Capital Markets analysts said in a research note. Shares have suffered due to self-inflicted issues that have contributed to low margins and stock rating downgrades, they added, noting that the stock ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRTN":"Triton International Limited","BK4104":"贸易公司与经销商"},"translate_title":"Triton收购股份后Evotec股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRTN":1},"content_text":"By Maitane Sardon \n\n\n \n\n\n  Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock. \n\n\n  Luxembourg-based private equity firm Triton acquired a total of  17,730,913 ordinary shares in a series of transactions totaling 131 million euros ($140.4 million), the German biotechnology company said. \n\n\n  Shares traded 12% higher at 8.52 euros in European early morning trading on Monday. \n\n\n  Triton, which also owns pharmaceutical services companies Bormioli Pharma and Clinigen, now holds 9.99% of Evotec's stock. \n\n\n  Evotec's market performance remains one of the worst in the sector so far this year, with shares down more than 60% over the last 12 months. \n\n\n  \"In a risk-off environment, Evotec's mixed model that includes sharing risk with partners, plus its internal product R&D, aren't appreciated by investors,\" RBC Capital Markets analysts said in a research note. Shares have suffered due to self-inflicted issues that have contributed to low margins and stock rating downgrades, they added, noting that the stock can outperform in the long term, potentially catalyzed by Triton's stock acquisition. \n\n\n \n\n\n  Write to Maitane Sardon at maitane.sardon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 05:22 ET (10:22 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482206659"}